




Searching News Database: solid tumors
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 13 Jun 2023
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian(R) MRI-Guided Radiation Therapy System
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian(R) MRI-Guided Radiation Therapy System
HSMN NewsFeed - 28 Feb 2023
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor
HSMN NewsFeed - 3 Feb 2023
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
HSMN NewsFeed - 9 Jan 2023
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
HSMN NewsFeed - 20 Sep 2022
MD Anderson Cancer Center Selects ViewRay to Expand MR-Guided Radiation Therapy Program
MD Anderson Cancer Center Selects ViewRay to Expand MR-Guided Radiation Therapy Program
HSMN NewsFeed - 7 Sep 2022
ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients
ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients
HSMN NewsFeed - 24 Aug 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
HSMN NewsFeed - 23 Aug 2022
VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
HSMN NewsFeed - 29 Jul 2022
Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
HSMN NewsFeed - 19 Jul 2022
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
HSMN NewsFeed - 13 Jul 2022
Immunitas Therapeutics Appoints Lynette Herscha as Chief Operating Officer
Immunitas Therapeutics Appoints Lynette Herscha as Chief Operating Officer
HSMN NewsFeed - 9 Jun 2022
VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
HSMN NewsFeed - 2 Jun 2022
Henry Ford Health Becomes the First Center to Treat Patients with ViewRay's MRIdian A3i System
Henry Ford Health Becomes the First Center to Treat Patients with ViewRay's MRIdian A3i System
HSMN NewsFeed - 3 May 2022
UCI Health Adopts ViewRay(R) MRIdian(R) MRI-Guided Radiation Therapy System
UCI Health Adopts ViewRay(R) MRIdian(R) MRI-Guided Radiation Therapy System
HSMN NewsFeed - 28 Mar 2022
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
HSMN NewsFeed - 17 Jan 2022
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
HSMN NewsFeed - 15 Dec 2021
ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features
ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features
HSMN NewsFeed - 9 Nov 2021
Ichnos Sciences Appoints Sonia Quaratino, M.D., Ph.D., To Its Board Of Directors
Ichnos Sciences Appoints Sonia Quaratino, M.D., Ph.D., To Its Board Of Directors
HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
HSMN NewsFeed - 25 Oct 2021
Helsinki University Hospital Selects MRIdian(R) System for Installation at Comprehensive Cancer Center
Helsinki University Hospital Selects MRIdian(R) System for Installation at Comprehensive Cancer Center
HSMN NewsFeed - 8 Oct 2021
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
HSMN NewsFeed - 7 Oct 2021
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
HSMN NewsFeed - 27 Sep 2021
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
HSMN NewsFeed - 8 Sep 2021
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
HSMN NewsFeed - 27 Jul 2021
Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
HSMN NewsFeed - 8 Jun 2021
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
HSMN NewsFeed - 1 Jun 2021
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
HSMN NewsFeed - 26 Jan 2021
The Henry Ford Cancer Institute Installs its Second ViewRay MRIdian(R) Linac
The Henry Ford Cancer Institute Installs its Second ViewRay MRIdian(R) Linac
HSMN NewsFeed - 18 Jan 2021
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
HSMN NewsFeed - 11 Jan 2021
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
HSMN NewsFeed - 26 Oct 2020
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
HSMN NewsFeed - 14 Oct 2020
Louis Stokes Cleveland VA Medical Center Purchases ViewRay's MRIdian Linac for MRI-Guided Radiation Therapy
Louis Stokes Cleveland VA Medical Center Purchases ViewRay's MRIdian Linac for MRI-Guided Radiation Therapy
HSMN NewsFeed - 29 Sep 2020
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
HSMN NewsFeed - 13 Aug 2020
Dartmouth-Hitchcock Health Begins Patient Treatments with ViewRay's MRIdian Linac
Dartmouth-Hitchcock Health Begins Patient Treatments with ViewRay's MRIdian Linac
HSMN NewsFeed - 8 Jul 2020
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
HSMN NewsFeed - 22 Jun 2020
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
HSMN NewsFeed - 16 Jun 2020
EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
HSMN NewsFeed - 4 Jun 2020
Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round
Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round
HSMN NewsFeed - 27 May 2020
Providence Portland Medical Center Begins Patient Treatments with ViewRay's MRIdian Linac
Providence Portland Medical Center Begins Patient Treatments with ViewRay's MRIdian Linac
HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
HSMN NewsFeed - 19 May 2020
BioEclipse Therapeutics(TM) Announces Move to New Corporate Headquarters in Mountain View, CA
BioEclipse Therapeutics(TM) Announces Move to New Corporate Headquarters in Mountain View, CA
HSMN NewsFeed - 8 Apr 2020
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
HSMN NewsFeed - 25 Mar 2020
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
HSMN NewsFeed - 12 Mar 2020
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
HSMN NewsFeed - 8 Jan 2020
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
HSMN NewsFeed - 8 Jan 2020
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
HSMN NewsFeed - 6 Jan 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
HSMN NewsFeed - 2 Jan 2020
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
HSMN NewsFeed - 19 Dec 2019
Michigan Community Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
Michigan Community Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
HSMN NewsFeed - 16 Dec 2019
Anixa Biosciences Announces Commercial Launch of Cchek(TM) Prostate Cancer Confirmatory Test
Anixa Biosciences Announces Commercial Launch of Cchek(TM) Prostate Cancer Confirmatory Test
HSMN NewsFeed - 22 Nov 2019
Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek(TM) Prostate Cancer Study
Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek(TM) Prostate Cancer Study
HSMN NewsFeed - 28 Oct 2019
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
HSMN NewsFeed - 10 Sep 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
HSMN NewsFeed - 24 Jun 2019
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
HSMN NewsFeed - 31 May 2019
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
HSMN NewsFeed - 2 Apr 2019
Petra Pharma Strengthens Management Team with Recent Leadership Appointments
Petra Pharma Strengthens Management Team with Recent Leadership Appointments
HSMN NewsFeed - 20 Mar 2019
Petra Pharma announces licensing agreement with Takeda Pharmaceutical Company
Petra Pharma announces licensing agreement with Takeda Pharmaceutical Company
HSMN NewsFeed - 25 Feb 2019
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
HSMN NewsFeed - 24 Oct 2018
Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek(TM) Cancer Diagnostic Test
Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek(TM) Cancer Diagnostic Test
HSMN NewsFeed - 17 Oct 2018
Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
HSMN NewsFeed - 15 Oct 2018
Medivir to Focus on its Clinical Development and Appoints Uli Hacksell as Acting CEO
Medivir to Focus on its Clinical Development and Appoints Uli Hacksell as Acting CEO
HSMN NewsFeed - 28 Sep 2018
ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
HSMN NewsFeed - 17 Sep 2018
ORIC Pharmaceuticals Appoints Pratik Multani, MD, as Chief Medical Officer
ORIC Pharmaceuticals Appoints Pratik Multani, MD, as Chief Medical Officer
HSMN NewsFeed - 5 Sep 2018
Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer
Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer
HSMN NewsFeed - 24 Aug 2018
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
HSMN NewsFeed - 21 Aug 2018
Alpha Tau's High-Precision Cancer Radiotherapy Receives Radioactive-Safety Approval in the United States
Alpha Tau's High-Precision Cancer Radiotherapy Receives Radioactive-Safety Approval in the United States
HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
HSMN NewsFeed - 12 Jun 2018
Vergent Bioscience Raises $8.7 Million in Series A Financing Led by Spring Mountain Capital
Vergent Bioscience Raises $8.7 Million in Series A Financing Led by Spring Mountain Capital
HSMN NewsFeed - 10 Apr 2018
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
HSMN NewsFeed - 21 Mar 2018
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
HSMN NewsFeed - 15 Feb 2018
Arterys Receives First FDA Clearance for Broad Oncology Imaging Suite with Deep Learning
Arterys Receives First FDA Clearance for Broad Oncology Imaging Suite with Deep Learning
HSMN NewsFeed - 16 Jan 2018
RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
HSMN NewsFeed - 30 Nov 2017
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
HSMN NewsFeed - 2 Aug 2017
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 13 Jul 2017
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
HSMN NewsFeed - 4 Jul 2017
FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy
FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy
HSMN NewsFeed - 29 Jun 2017
Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe
Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe
HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
HSMN NewsFeed - 13 Apr 2017
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg
HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
HSMN NewsFeed - 27 Jan 2017
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
HSMN NewsFeed - 12 Oct 2016
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 4 Aug 2016
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
HSMN NewsFeed - 1 Aug 2016
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
HSMN NewsFeed - 22 Jun 2016
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
HSMN NewsFeed - 11 Jan 2016
Iconic Therapeutics Closes Series C Financing With New and Existing Investors
Iconic Therapeutics Closes Series C Financing With New and Existing Investors
HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 19 Nov 2015
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
HSMN NewsFeed - 29 Oct 2015
Bellicum Appoints Alan K. Smith as Senior Vice President of Manufacturing
Bellicum Appoints Alan K. Smith as Senior Vice President of Manufacturing
HSMN NewsFeed - 27 Oct 2015
Mirna Therapeutics Appoints Dr. Miguel Barbosa as Executive Vice President and Chief Scientific Officer
Mirna Therapeutics Appoints Dr. Miguel Barbosa as Executive Vice President and Chief Scientific Officer
HSMN NewsFeed - 5 Oct 2015
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
HSMN NewsFeed - 14 Jul 2015
Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma
Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma
HSMN NewsFeed - 31 Mar 2015
Tyrogenex, Xcovery Appoint Michael Webb as President and Chief Executive Officer
Tyrogenex, Xcovery Appoint Michael Webb as President and Chief Executive Officer
HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
HSMN NewsFeed - 20 Mar 2015
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
HSMN NewsFeed - 29 Oct 2014
Aileron Therapeutics Secures $33 Million in Series E Financing to Advance Its First-In-Class Cancer Drug
Aileron Therapeutics Secures $33 Million in Series E Financing to Advance Its First-In-Class Cancer Drug
HSMN NewsFeed - 11 Sep 2014
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
HSMN NewsFeed - 8 Aug 2014
Karyopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer
Karyopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer
HSMN NewsFeed - 19 Jun 2014
Tyrogenex Raises $15M in Series D Financing from Brace Pharma, US Investment Arm of EMS S/A
Tyrogenex Raises $15M in Series D Financing from Brace Pharma, US Investment Arm of EMS S/A
HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
HSMN NewsFeed - 26 Mar 2014
Bio-Path Holdings, Inc. Appoints Ulrich W. Mueller Chief Operating Officer
Bio-Path Holdings, Inc. Appoints Ulrich W. Mueller Chief Operating Officer
HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
HSMN NewsFeed - 13 Jan 2014
Arno Therapeutics Expands Management Team With Additions of Two Scientific Leaders
Arno Therapeutics Expands Management Team With Additions of Two Scientific Leaders
HSMN NewsFeed - 7 Jan 2014
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
HSMN NewsFeed - 2 Jan 2014
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
HSMN NewsFeed - 1 Oct 2013
BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer
BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer
HSMN NewsFeed - 1 Oct 2013
First urine-based cancer mutation monitoring test available from Trovagene
First urine-based cancer mutation monitoring test available from Trovagene
HSMN NewsFeed - 20 Aug 2013
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
HSMN NewsFeed - 31 Jul 2013
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
HSMN NewsFeed - 13 Jun 2013
FDA Approves Amgen's XGEVA(R) (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
FDA Approves Amgen's XGEVA(R) (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
HSMN NewsFeed - 13 Jun 2013
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
HSMN NewsFeed - 5 Jun 2013
Johnson & Johnson Innovation Announces Opening of the California Innovation Center
Johnson & Johnson Innovation Announces Opening of the California Innovation Center
HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
HSMN NewsFeed - 19 Feb 2013
MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO
MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO
HSMN NewsFeed - 22 Jan 2013
NCCN Guidelines(R) Recommend NovoTTF(TM) Therapy as a Standard Treatment Option for CNS Cancers
NCCN Guidelines(R) Recommend NovoTTF(TM) Therapy as a Standard Treatment Option for CNS Cancers
HSMN NewsFeed - 22 Jan 2013
Tau Therapeutics Hires Chief Medical Officer and VP of Operations and Strategy
Tau Therapeutics Hires Chief Medical Officer and VP of Operations and Strategy
HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
HSMN NewsFeed - 28 Nov 2012
Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
HSMN NewsFeed - 21 Nov 2012
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
HSMN NewsFeed - 13 Nov 2012
Epic Sciences Announces Series B Financing to Advance Essential Cancer Diagnostics for Personalized Medicine
Epic Sciences Announces Series B Financing to Advance Essential Cancer Diagnostics for Personalized Medicine
Additional items found! 497

Members Archive contains
497 additional stories matching:
solid tumors
(Password required)
solid tumors
(Password required)